Clozapine for psychosis in Parkinson's disease

Ronald F. Pfeiffer, Jasbir Kang, Benjamin Graber, Ruth Hofman, James Wilson

Research output: Contribution to journalArticlepeer-review

93 Scopus citations


The clinical efficacy of clozapine, an atypical antipsychotic, in treating levodopa‐induced hallucinations was investigated in five patients with Parkinson's disease under open label conditions. Two patients could not tolerate clozapine, even in doses as low as 12.5–25 mg daily, because of extreme sedation. Three patients could tolerate clozapine and experienced improvement or elimination of their hallucinations at doses below 100 mg daily. Despite a significant risk of adverse effects, cautious use of clozapine in low doses may be beneficial for patients with levodopa‐induced psychosis who do not respond to more conservative measures.

Original languageEnglish (US)
Pages (from-to)239-242
Number of pages4
JournalMovement Disorders
Issue number3
StatePublished - 1990


  • Clozapine
  • Parkinson's disease
  • Psychosis

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology


Dive into the research topics of 'Clozapine for psychosis in Parkinson's disease'. Together they form a unique fingerprint.

Cite this